ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1035

The ELSA-Brasil Musculoskeletal Cohort (ELSA-Brasil MSK): Design, Implementation and Prevalence of Chronic Musculoskeletal Pain and Radiographic Knee Osteoarthritis at Baseline

Rosa Weiss Telles1, Luciana Machado2, Luciana Costa-Silva3 and Sandhi Maria Barreto1, 1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2Clinical Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 3Instituto Hermes Pardini. Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Meeting: ACR Convergence 2021

Keywords: Cohort Study, Epidemiology, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Musculoskeletal (MSK) disorders, including low back pain and osteoarthritis (OA), are ranked among the top causes of years lived with disability and increased risk-attributable disability-adjusted life-years. ELSA-Brasil MSK is an ancillary study of the ELSA-Brasil that investigates the incidence and risk factors for MSK disorders. Here we briefly describe the design and implementation of the cohort and presented prevalence of chronic musculoskeletal pain (CMP) and knee OA at baseline.

Methods: ELSA-Brasil MSK includes active and retired civil servants from one of the investigation centers (IC) of ELSA-Brasil (IC-Minas Gerais) who completed assessments on five different domains concerning MSK health (rheumatic diseases and symptoms; disability and physical functioning; mechanical risk factors; personal beliefs; care seeking) at study baseline (2012-2014). Cohort surveillance has been performed through annual telephone interviews and return visits (scheduled every 4 years after enrollment), collecting extensive information on exposures, subclinical and clinical outcomes. A total of 2,901 participants were assessed for CMP (≥ 6 months in the past year) at nine body sites: neck, shoulders, upper back, elbows, lower back, wrists/hands, hips/thighs, knees, ankles/feet. CMP was described as multisite ( >3 sites) and generalized (3 regions: upper + lower limbs + axial skeleton). 2,830 participants underwent hand and/or knee radiography for the diagnosis of OA along with the assessment of frequent hand/knee pain (pain on most days of at least 1 month). Radiographic knee OA (RKOA) was defined as the presence of tibiofemoral (TF) (KL ≥2) and/or patellofemoral (PF) (definitive osteophyte ≥2 or joint space narrowing ≥2 +bone abnormality) OA and symptomatic knee OA (SKOA) as the presence of RKOA + frequent knee pain in the corresponding knee.

Results: Participants were aged between 38 and 79 years old (mean 56.0 SD 8.9), 52.9% were women. CMP in at least one site was observed in 55.1% of participants and there was a high prevalence of multisite (19.1%) and generalized (10.3%) CMP. CMP was more commonly observed among females and participants who were older, non-white, less educated, retired, with depression, and those with higher body mass index and number of comorbidities (Table 1). The prevalence RKOA and SKOA was 18.1% and 7.8%, respectively. TF compartment was scored as KL in 2 in 7.6%, 3 in 3.0% and 4 in 1.1% of 5,638 knee images (Table 2). Most knees with RKOA (n=740) showed isolated TF OA (56.6%), with isolated PF OA in 11.4% of knees (Figure 1).

Conclusion: The high prevalence of CMP and knee OA indicates a large burden of MSK disorders in Brazil. Future longitudinal analyses in ELSA-Brasil MSK will provide an unique opportunity to fill current knowledge gaps about psychosocial and biological determinants of these disorders in a middle-income country.

Funding: ELSA-Brasil is supported by the Brazilian Ministry of Health and of Science and Technology (FINEP and CNPq-BR), (Grants 01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ). ELSA-Brasil MSK has been supported by CAPES-BR (054/2010), FAPEMIG-BR (APQ-00921-16) and CNPq-BR (42358520169).

BMI, body mass index. MSK, musculoskeletal. CMP, chronic musculoskeletal pain. CLBP, chronic low back pain. aComorbidity: hypertension, diabetes, myocardial infarction, heart failure, stroke, kidney disease, COPD, cirrhosis, cancer.

Figure 1 Venn Diagram of radiographic OA in ELSA-Brasil MSK (n=5,636 knees*, 2012_2014) *n=5,636 knees tibiofemoral and patellofemoral radiographic images


Disclosures: R. Weiss Telles, GSK Brasil, 12, Financial support to participate in medical events; L. Machado, None; L. Costa-Silva, None; S. Maria Barreto, None.

To cite this abstract in AMA style:

Weiss Telles R, Machado L, Costa-Silva L, Maria Barreto S. The ELSA-Brasil Musculoskeletal Cohort (ELSA-Brasil MSK): Design, Implementation and Prevalence of Chronic Musculoskeletal Pain and Radiographic Knee Osteoarthritis at Baseline [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-elsa-brasil-musculoskeletal-cohort-elsa-brasil-msk-design-implementation-and-prevalence-of-chronic-musculoskeletal-pain-and-radiographic-knee-osteoarthritis-at-baseline/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-elsa-brasil-musculoskeletal-cohort-elsa-brasil-msk-design-implementation-and-prevalence-of-chronic-musculoskeletal-pain-and-radiographic-knee-osteoarthritis-at-baseline/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology